Stockscreener 앱 받기
190.11
0.55%
1.04
Ligand Pharmaceuticals Inc 주식(LGND)의 최신 뉴스
Moody Aldrich Partners LLC Buys Shares of 25,884 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Calamos Advisors LLC Grows Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView — Track All Markets
Ligand Pharmaceuticals Earnings Notes - Trefis
Loss Report: How Ligand Pharmaceuticals Incorporated stock reacts to bond yieldsTrade Analysis Report & Daily Market Momentum Tracking - moha.gov.vn
Ligand Pharmaceuticals Incorporated $LGND Position Trimmed by Rice Hall James & Associates LLC - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2025 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (LGND) Price Target Increased by 24.57% to 232.69 - MSN
Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Price Target Increased by 23.15% to 0.01 - Nasdaq
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Increased by Congress Asset Management Co. - MarketBeat
Published on: 2025-12-20 22:34:37 - Улправда
Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Earnings Impact & Community Consensus Stock Picks - Улправда
Can Ligand Pharmaceuticals Incorporated stock rebound after recent weaknessEarnings Performance Report & Free Verified High Yield Trade Plans - Улправда
How sustainable is Ligand Pharmaceuticals Incorporated stock dividend payoutJuly 2025 Action & Low Volatility Stock Recommendations - Улправда
Is Ligand Pharmaceuticals Incorporated stock positioned well for digital economyMarket Sentiment Report & Growth Focused Stock Pick Reports - DonanımHaber
Octavio Espinoza At Ligand Pharmaceuticals Capitalizes: Options Exercised, Resulting In $308K - Benzinga
Ligand Pharmaceuticals backs Athira Pharmas 90 million funding round - Traders Union
Will Ligand Pharmaceuticals Incorporated stock deliver better than expected guidance2025 Growth vs Value & Weekly High Conviction Ideas - Улправда
[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Published on: 2025-12-19 00:15:21 - Улправда
Why Ligand Pharmaceuticals Incorporated stock could outperform in 2025July 2025 Technicals & Proven Capital Preservation Methods - Улправда
Gains Recap: Will Ligand Pharmaceuticals Incorporated stock continue upward momentum2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan
Woodstock Corp Sells 9,472 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
FY2026 Earnings Forecast for LGND Issued By Zacks Small Cap - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue? - Yahoo Finance
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView — Track All Markets
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $339,711.24 in Stock - MarketBeat
LGND: 2025 Analyst Day - Zacks Small Cap Research
Ligand Pharmaceuticals Incorporated $LGND Stock Holdings Raised by Ranger Investment Management L.P. - MarketBeat
Market Leaders: Is Ligand Pharmaceuticals Incorporated stock safe for conservative investorsPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - moha.gov.vn
CFO Espinoza Files To Sell 1,804 Of Ligand Pharmaceuticals Inc [LGND] - TradingView — Track All Markets
What is HC Wainwright's Forecast for LGND FY2026 Earnings? - MarketBeat
RBC Capital Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNDZ) Outperform Recommendation - Nasdaq
Norges Bank Acquires Shares of 14,073 Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
RBC Capital Maintains Ligand Pharmaceuticals (LGND) Outperform Recommendation - Nasdaq
Stifel Maintains Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Buy Recommendation - Nasdaq
Benchmark reaffirms Buy rating on Ligand Pharma stock with $220 target - Investing.com Canada
Oppenheimer reiterates Outperform rating on Ligand Pharma stock at $275 By Investing.com - Investing.com Canada
LGND: RBC Capital Raises Price Target, Maintains 'Outperform' Ra - GuruFocus
LGND: Stifel Raises Price Target to $230, Maintains 'Buy' Rating - GuruFocus
Stifel Nicolaus Boosts Ligand Pharmaceuticals (NASDAQ:LGND) Price Target to $230.00 - MarketBeat
RBC Lifts Price Target on Ligand Pharmaceuticals to $235 From $234, Keeps Outperform Rating - marketscreener.com
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance - 富途牛牛
CFO Espinoza Surrenders 1,862 Of Ligand Pharmaceuticals Inc [LGND] - TradingView — Track All Markets
Ligand Pharma stock price target raised to $230 by Stifel on growth outlook - Investing.com Canada
Citigroup Initiates Coverage of Ligand Pharmaceuticals (LGND) with Buy Recommendation - Nasdaq
LIGAND PHARMACEUTICALS INCINTRODUCES 2026 REVENUE GUIDANCE OF $245-$285 MLN - 富途牛牛
Citigroup Initiates Coverage On LGND with a Buy Rating | LGND St - GuruFocus
Ligand Pharma sets 2026 outlook as Citi starts at buy on valuation - MSN
Major Decision: Jason Aryeh Exercises Options, Realizing $234K At Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY 2026 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Coverage Initiated by Analysts at Citigroup - MarketBeat
Ligand Pharmaceuticals Stock (LGND) Opinions on 2025 Investor Day and 2026 Guidance - Quiver Quantitative
Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2026 - marketscreener.com
Citigroup Initiates Ligand Pharmaceuticals at Buy With $270 Price Target - marketscreener.com
Ligand (LGND) Reaffirms 2025 Financial Outlook - GuruFocus
(LGND) Ligand Pharmaceuticals Expects Full Year 2025 Core Revenue Range $225M to $235M - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects Full Year 2026 Core Adjusted EPS Range $8 to $9, vs. FactSet Est of $7.97 - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects Full Year 2026 Revenue Range $245M to $285M, vs. FactSet Est of $259.2M - marketscreener.com
LGND FinancialsIncome Statement - Quiver Quantitative
Ligand Pharmaceuticals Provides 2026 Revenue Guidance of $245 Million to $285 Million with Increased Royalty Revenue Outlook - Quiver Quantitative
0.57%
자본화:
|
볼륨(24시간):